| Lemoli, Roberto M |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 3 | 350 | Europe, Canada, US, RoW | Selinexor, KPT-330, Placebo, Ruxolitinib | Karyopharm Therapeutics Inc | Myelofibrosis | 09/25 | 03/28 | | |
|
|
|
|
|
|
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
| Terminated | 2 | 25 | Europe | tagraxofusp | Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia | 01/24 | 01/24 | | |
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
|
|
| Recruiting | 2 | 118 | Europe, Canada, US, RoW | Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA | Karyopharm Therapeutics Inc | Myelofibrosis, Moderate Thrombocytopenia | 04/26 | 10/28 | | |
| Completed | N/A | 1150 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Polycythemia Vera | 12/23 | 12/23 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia |
|
|
| Active, not recruiting | N/A | 75 | Europe | Immunogenic profile | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera |
|
|
| Recruiting | N/A | 1055 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis | 05/32 | 05/32 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
INTHEMA, NCT04298892: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies |
|
|
| Recruiting | N/A | 2000 | Europe | clinical data and sample collection | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Azienda Unità Sanitaria Locale della Romagna | Haematologic Disease, Haematological Malignancy | 02/25 | 02/25 | | |
